Did Moderna Start Developing Hantavirus mRNA Vaccine in 2024? What We Know
Summary
Moderna started early research in 2024 on an mRNA vaccine targeting hantaviruses, focusing on strains common in Asia and Europe, not the United States. This work is part of a scientific effort to improve vaccines and is not linked to any ongoing U.S. outbreak or government vaccination program.Key Facts
- Moderna is collaborating with Korea University on early-stage, preclinical research for a hantavirus mRNA vaccine.
- The research focuses on hantaviruses causing Hemorrhagic Fever with Renal Syndrome (HFRS), mainly found in East Asia and parts of Europe.
- South Korea reports 300 to 400 HFRS cases each year, mostly among military personnel and people in rural areas.
- Hantavirus is a family of viruses with different strains in various parts of the world; vaccines may not protect against all strains.
- Moderna's vaccine aims to provide broader protection against multiple hantavirus strains.
- The vaccine development is unrelated to the Sin Nombre virus strain, which causes hantavirus cases in the U.S. and leads to Hantavirus Pulmonary Syndrome (HPS).
- There is no approved hantavirus vaccine currently available in the U.S.
- Some social media posts falsely claim Moderna’s work is tied to secret or political agendas, but the research is standard scientific progress.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.